Moreover, NSCLC patients with EGFR/TP53/RB1 mutations or with apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC)–induced hypermutation may be at increased risk of transformation [53, 54]. This evidence concerns the gene RB1 and non-small cell lung carcinoma.